Pharma News

Premature birth, a leading cause of death of newborns worldwide, could be prevented by blocking a molecule in the uterus, suggests a new research.

Bioactive glass can be used in tooth fillings to reduce the ability of bacteria to attack composite tooth fillings, and perhaps even provide some of the minerals needed to replace those lost to tooth decay, engineers from Oregon State University said.

[adsense:336x280:8701650588]

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the intended treatment of acute pain, reported that the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) has confirmed that a Marketing Authorization Application (MAA) for ARX-04 may be submitted in the European Union (EU) under the Agency's centralized procedure. ARX-04 (sufentanil sublingual tablet, 30 mcg) is being developed for the treatment of moderate-to-severe acute pain in adult patients administered by a healthcare professional in a medically supervised setting.

Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Famotidine Tablets USP, 20 mg and 40 mg.

Celgene Corporation announced the settlement of litigation with Natco Pharma Ltd. of India, Natco's U.S. partner, Arrow International Limited, and Arrow's parent company, Watson Laboratories, Inc. (a wholly-owned subsidiary of Allergan plc) relating to patents for REVLIMID® (lenalidomide).

New research has revealed how malaria parasites cause an inflammatory reaction that sabotages our body's ability to protect itself against the disease.

Can the emergence of antibiotic-resistant bacteria be squarely blamed on the misuse and overuse of antibiotics? No, there is more to the problem than the misuse of common medications, says a University of Georgia researcher.

Merck, known as MSD outside the United States and Canada, announced that the application for Emergency Use Assessment and Listing (EUAL) for the company’s investigational Ebola Zaire vaccine, V920 (rVSV?G-ZEBOV-GP, live attenuated), has been accepted for review by the World Health Organization (WHO).

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation announced that REVLIMID® (lenalidomide), a cancer medicine that is administered orally, has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for use in combination with dexamethasone as a treatment for patients newly diagnosed with multiple myeloma. This marketing authorization expands upon the approval of REVLIMID in 2010 for the treatment of patients with relapsed or refractory multiple myeloma.